Novartis has applied for the registration of insurance benefits for another new one-shot gene therapy drug.

According to related industries, Novartis Korea recently submitted an application for benefits for the Inherited Retinal Dystrophy (IRD) treatment "Luxturna (Voregenene Neparvovec).

Luxturna restores its function by replacing the deficiency and defective RPE65 gene, one of the causes of IRD, with a normal gene with just one administration. In other words, fundamental treatment of diseases is possible.

The drug was designated by the U.S. FDA as a target for Breakthrough Therapy in 2014, Orphan Drug in 2016, and Priority Review in 2017, and obtained rapid approval in 20